151 related articles for article (PubMed ID: 35221159)
21. Health-related quality of life (HRQoL), anxiety, and depression in patients with desmoid type fibromatosis.
Garg V; Rastogi S; Kalra K; Bhoriwal S; Barwad A; Dhamija E; Upadhyay A; Gamangatti S
Support Care Cancer; 2022 Dec; 30(12):10089-10098. PubMed ID: 36350382
[TBL] [Abstract][Full Text] [Related]
22. Physical symptom burden in patients with desmoid-type fibromatosis and its impact on health-related quality of life and healthcare use.
Schut AW; de Bruin LE; de Rooij BH; Lidington E; Timbergen MJM; van der Graaf WTA; van Houdt WJ; Bonenkamp JJ; Jones RL; Grünhagen DJ; Sleijfer S; Gennatas S; Verhoef C; Husson O
Cancer Med; 2023 Jun; 12(12):13661-13674. PubMed ID: 37119048
[TBL] [Abstract][Full Text] [Related]
23. Iron chelator deferasirox inhibits NF-κB activity in hepatoma cells and changes sorafenib-induced programmed cell deaths.
Jomen W; Ohtake T; Akita T; Suto D; Yagi H; Osawa Y; Kohgo Y
Biomed Pharmacother; 2022 Sep; 153():113363. PubMed ID: 35834989
[TBL] [Abstract][Full Text] [Related]
24. PDGFRβ Signaling Cooperates with β-Catenin to Modulate c-Abl and Biologic Behavior of Desmoid-Type Fibromatosis.
Hu J; Hameed MR; Agaram NP; Whiting KA; Qin LX; Villano AM; O'Connor RB; Rozenberg JM; Cohen S; Prendergast K; Kryeziu S; White RL; Posner MC; Socci ND; Gounder MM; Singer S; Crago AM
Clin Cancer Res; 2024 Jan; 30(2):450-461. PubMed ID: 37943631
[TBL] [Abstract][Full Text] [Related]
25. SPARC regulates ferroptosis induced by sorafenib in human hepatocellular carcinoma.
Hua HW; Jiang HS; Jia L; Jia YP; Yao YL; Chen YW; Jiang F; Lu DQ; Zhou Q; Jiang MW; Ding G
Cancer Biomark; 2021; 32(4):425-433. PubMed ID: 33843664
[TBL] [Abstract][Full Text] [Related]
26. Extra-abdominal aggressive fibromatosis treated with meloxicam and sorafenib: An encouraging option.
Sari M
J Cancer Res Ther; 2020; 16(4):900-902. PubMed ID: 32930137
[TBL] [Abstract][Full Text] [Related]
27. Sorafenib induces mitochondrial dysfunction and exhibits synergistic effect with cysteine depletion by promoting HCC cells ferroptosis.
Li Y; Xia J; Shao F; Zhou Y; Yu J; Wu H; Du J; Ren X
Biochem Biophys Res Commun; 2021 Jan; 534():877-884. PubMed ID: 33162029
[TBL] [Abstract][Full Text] [Related]
28. Identification and assessment of health-related quality of life issues in patients with sporadic desmoid-type fibromatosis: a literature review and focus group study.
Timbergen MJM; van de Poll-Franse LV; Grünhagen DJ; van der Graaf WT; Sleijfer S; Verhoef C; Husson O
Qual Life Res; 2018 Dec; 27(12):3097-3111. PubMed ID: 30014458
[TBL] [Abstract][Full Text] [Related]
29. Differentially Methylated Regions in Desmoid-Type Fibromatosis: A Comparison Between CTNNB1 S45F and T41A Tumors.
Timbergen MJM; Boers R; Vriends ALM; Boers J; van IJcken WFJ; Lavrijsen M; Grünhagen DJ; Verhoef C; Sleijfer S; Smits R; Gribnau J; Wiemer EAC
Front Oncol; 2020; 10():565031. PubMed ID: 33194643
[TBL] [Abstract][Full Text] [Related]
30. Activated Signaling Pathways and Targeted Therapies in Desmoid-Type Fibromatosis: A Literature Review.
Timbergen MJM; Smits R; Grünhagen DJ; Verhoef C; Sleijfer S; Wiemer EAC
Front Oncol; 2019; 9():397. PubMed ID: 31165043
[TBL] [Abstract][Full Text] [Related]
31. Induction of Apoptosis, Autophagy and Ferroptosis by
N Adham A; F Hegazy ME; Naqishbandi AM; Efferth T
Molecules; 2020 Oct; 25(21):. PubMed ID: 33138135
[No Abstract] [Full Text] [Related]
32. Papillary thyroid cancer with extrathyroidal extension of desmoid-type fibromatosis. A case report of an aggressive presentation of an uncommon pathologic entity.
Roth EM; Barrows CE; Nishino M; Sacks B; Hasselgren PO; James BC
Int J Surg Case Rep; 2019; 63():5-9. PubMed ID: 31499326
[TBL] [Abstract][Full Text] [Related]
33. Inhibition of autophagy potentiates the antitumor effect of the multikinase inhibitor sorafenib in hepatocellular carcinoma.
Shimizu S; Takehara T; Hikita H; Kodama T; Tsunematsu H; Miyagi T; Hosui A; Ishida H; Tatsumi T; Kanto T; Hiramatsu N; Fujita N; Yoshimori T; Hayashi N
Int J Cancer; 2012 Aug; 131(3):548-57. PubMed ID: 21858812
[TBL] [Abstract][Full Text] [Related]
34. Radiation-induced Sarcomas Occurring in Desmoid-type Fibromatosis Are Not Always Derived From the Primary Tumor.
Verschoor AJ; Cleton-Jansen AM; Wijers-Koster P; Coffin CM; Lazar AJ; Nout RA; Rubin BP; Gelderblom H; Bovée JV
Am J Surg Pathol; 2015 Dec; 39(12):1701-7. PubMed ID: 26414222
[TBL] [Abstract][Full Text] [Related]
35. Nuclear TFE3 expression is a diagnostic marker for Desmoid-type fibromatosis.
Zhou L; Xu H; Zhou J; Dong L; Zhang P; Yang X; Wang C
Diagn Pathol; 2019 May; 14(1):34. PubMed ID: 31043173
[TBL] [Abstract][Full Text] [Related]
36. Rationale for the use of tyrosine kinase inhibitors in the treatment of paediatric desmoid-type fibromatosis.
Sparber-Sauer M; Orbach D; Navid F; Hettmer S; Skapek S; Corradini N; Casanova M; Weiss A; Schwab M; Ferrari A
Br J Cancer; 2021 May; 124(10):1637-1646. PubMed ID: 33723397
[TBL] [Abstract][Full Text] [Related]
37. Amentoflavone suppresses cell proliferation and induces cell death through triggering autophagy-dependent ferroptosis in human glioma.
Chen Y; Li N; Wang H; Wang N; Peng H; Wang J; Li Y; Liu M; Li H; Zhang Y; Wang Z
Life Sci; 2020 Apr; 247():117425. PubMed ID: 32057904
[TBL] [Abstract][Full Text] [Related]
38. Iron-dependent cell death of hepatocellular carcinoma cells exposed to sorafenib.
Louandre C; Ezzoukhry Z; Godin C; Barbare JC; Mazière JC; Chauffert B; Galmiche A
Int J Cancer; 2013 Oct; 133(7):1732-42. PubMed ID: 23505071
[TBL] [Abstract][Full Text] [Related]
39. Role of tumor-associated macrophages and angiogenesis in desmoid-type fibromatosis.
Romero S; Szafranska J; Cabrera E; Gonzalez A; Peiró A; Llauger J; Ortega L; Bague S; Canet B; Espinosa I; Prat J
Virchows Arch; 2012 Aug; 461(2):117-22. PubMed ID: 22744289
[TBL] [Abstract][Full Text] [Related]
40. Desmoid-type fibromatosis: toward a holistic management.
Penel N; Kasper B; van Der Graaf WTA
Curr Opin Oncol; 2021 Jul; 33(4):309-314. PubMed ID: 33973549
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
